Prothena Corporation plc (PRTA) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reflects a mixed sentiment. Financial performance shows prudent capital utilization but also a significant net loss. The Q&A highlights promising developments in product trials and partnerships, but also reveals management's reluctance to provide detailed guidance, creating uncertainty. The share redemption plan indicates potential shareholder value but lacks immediate impact. Overall, the stock is likely to remain neutral, with no strong catalysts for significant movement. The market cap suggests moderate sensitivity to these factors.
Key Financial Performance
Net cash used in operating and investing activities (2025) $163.7 million, favorable to guidance range of $170 million to $178 million. The favorable result was due to efficient capital utilization.
Net loss (2025) $244.1 million, in line with guidance range of $240 million to $248 million. No specific reasons for the change were mentioned.
Cash, cash equivalents, and restricted cash (2025 year-end) $308.4 million, favorable to guidance of $298 million. The favorable result was due to prudent capital utilization.
Ordinary shares outstanding (as of February 12, 2026) 53.8 million. No year-over-year change or reasons for change were mentioned.
Debt (2025 year-end) $0, indicating a simple capital structure. No year-over-year change or reasons for change were mentioned.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Prasinezumab: Advanced into Phase III PARAISO trial for early Parkinson's disease with 900 participants. Demonstrated consistent slowing of disease progression in Phase II trials.
Coramitug: Advanced into Phase III CLEOPATTRA trial for ATTR-CM with 1,280 patients. Phase II results showed positive NT-proBNP and echocardiogram changes.
BMS-986446: Phase II TargetTau-1 trial for early Alzheimer's disease fully enrolled, with completion expected in 2027. Fast Track designation obtained from FDA.
PRX019: Phase I trial ongoing, expected completion in 2026.
CYTOPE Technology: Introduced for targeting intracellular disease pathways, with focus on TDP-43 for ALS.
ATTR-CM Market: Coramitug represents a multibillion-dollar market opportunity, with Prothena eligible for up to $1.13 billion in milestone payments.
Alzheimer's Market: BMS-986446 and PRX019 target a multibillion-dollar market opportunity, with potential milestone payments of $562.5 million and $617.5 million, respectively.
Parkinson's Market: Prasinezumab has a global peak sales opportunity greater than $3.5 billion, with Prothena eligible for up to $620 million in milestone payments.
Financial Performance: 2025 net cash used in operations was $163.7 million, favorable to guidance. Ended 2025 with $308.4 million in cash and no debt.
2026 Financial Guidance: Net cash used in operations expected to be $50-$55 million. Potential $105 million in milestone payments not included in guidance.
Clinical Partnerships: Focus on capturing value from partnerships, including potential $105 million in 2026 milestones.
Share Redemption Program: Approved and confirmed for 2026.
Preclinical Portfolio: Investing in CYTOPE technology and exploring research collaborations for future licensing deals.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory Approvals: The company faces risks related to obtaining necessary regulatory approvals for its clinical trials and programs, as highlighted by the mention of approvals from the Irish High Court and other regulatory bodies.
Clinical Trial Success: There is a risk of clinical trial failures or delays, as evidenced by the ongoing trials for prasinezumab, coramitug, and other programs, which have long timelines and uncertain outcomes.
Financial Dependence on Milestones: The company’s financial projections rely heavily on achieving up to $105 million in clinical milestone payments in 2026, which are contingent on the success of partner programs.
Market Competition: The company operates in highly competitive markets, such as treatments for Parkinson’s disease, Alzheimer’s disease, and ATTR-CM, where other companies are also developing therapies.
Economic Viability of Programs: The economic success of programs like prasinezumab and coramitug depends on achieving significant market penetration and demonstrating clear therapeutic differentiation.
Supply Chain and Operational Risks: Potential supply chain disruptions or operational challenges could impact the development and delivery of therapies.
Dependence on Partnerships: The company’s reliance on partnerships with large pharmaceutical companies like Roche, Novo Nordisk, and Bristol Myers Squibb introduces risks if these partners fail to meet their obligations or if collaborations are terminated.
Cash Flow and Capital Utilization: The company’s cash flow projections depend on prudent capital utilization and achieving financial milestones, with limited room for error given its $308.4 million cash balance.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
2026 Financial Guidance: Prothena expects full-year 2026 net cash used in operating and investing activities to be between $50 million and $55 million. The company anticipates ending the year with approximately $255 million in cash, cash equivalents, and restricted cash. The estimated net loss for 2026 is projected to be between $67 million and $72 million, including $24 million in non-cash share-based compensation expense. This guidance excludes up to $105 million in potential clinical milestone payments from strategic partners in 2026.
Clinical Milestone Payments: Prothena has the potential to earn up to $105 million in aggregate clinical milestone payments in 2026. These payments are contingent on the advancement of coramitug for ATTR amyloidosis with cardiomyopathy by Novo Nordisk and PRX019 for neurodegenerative diseases by Bristol Myers Squibb.
Clinical Trial Timelines: The Phase III PARAISO trial for prasinezumab in early Parkinson's disease, initiated by Roche, is expected to have primary completion in 2029. Similarly, the Phase III CLEOPATTRA trial for coramitug in ATTR-CM patients, initiated by Novo Nordisk, is also expected to have primary completion in 2029. The Phase II TargetTau-1 trial for BMS-986446 in early Alzheimer's disease, conducted by Bristol Myers Squibb, is expected to complete in the first half of 2027. Prothena's Phase I trial for PRX019 is on track for completion in 2026.
Future Milestone Payments: Prothena's four partner clinical programs have the potential to deliver up to approximately $3 billion in future milestone payments, in addition to royalties.
Strategic Priorities for 2026: Prothena aims to capture value from clinical partnerships, including potential milestone payments, implement a share redemption program, and invest in its preclinical portfolio to support ongoing partnering efforts, particularly for its CYTOPE technology.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Share Redemption Program: Prothena has received all necessary approvals from its extraordinary General Meeting of Shareholders and the Irish High Court to support a share redemption program in 2026.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What are the key milestones to look out for in 2026 and 2027 for the partnered program trials PARAISO and CLEOPATTRA?
A:Key milestones include sharing more information on CYTOPE activities, particularly the TDP-43 CYTOPE program, through scientific presentations in 2026. In the first half of 2027, data from the partner tau program with Bristol Myers Squibb is expected, focusing on tau PET as the primary outcome measure. Additionally, there are two Phase III readouts for coramitug and prasinezumab with primary completion dates in 2029. The company also plans to implement a share redemption program in 2023 and potentially achieve up to $105 million in clinical milestones from partners.
Q:How does Prothena plan to keep the amyloid data story alive with PRX012 against larger competitors?
A:Prothena is leveraging the transferrin-based approach for PRX012, which has shown promising results in amyloid removal with a once-monthly subcutaneous administration. The company believes this approach could improve the ARIA-E profile and enhance amyloid removal. They are also exploring the potential of the transferrin receptor platform to address limitations of anti-Abeta antibodies and improve the primary mechanism of action. Prothena is actively engaging in business development discussions and sees potential in the presymptomatic Alzheimer's space.
Q:Will Prothena share data from the Phase I study of PRX019 this year, and what is required for the program to advance?
A:The Phase I study of PRX019 is expected to complete this year, and the data will be shared with Bristol Myers Squibb, who has global rights to the program. Prothena will announce if the molecule advances into further clinical development, which would trigger clinical milestone payments. The decision to share data publicly lies with Bristol Myers Squibb.
Q:What data is necessary to secure a partnership for the CYTOPE platform, or to advance the program into the clinic independently?
A:Prothena has demonstrated the CYTOPE platform's ability to target intracellular TDP-43 aggregates in ALS models with systemic administration and robust CNS activity. The company is engaging in research collaborations to validate the technology across various therapeutic areas. To advance the program independently, Prothena would need to see further validation of the platform's efficacy and safety in preclinical and early clinical studies.
Q:What are the mechanistic hypotheses for why the transferrin modification reduces ARIA risk in PRX012, and will it still allow subcutaneous delivery?
A:The transferrin modification may reduce ARIA risk by altering the route of entry into the brain, potentially through capillary structures rather than arterial structures, or by minimizing the dwell time of the antibody on amyloid in the vasculature. Prothena believes the transferrin modification will still allow for subcutaneous delivery of PRX012, leveraging its potency to achieve biological effects at lower doses.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on the target of PRX019, citing strategic reasons. They also did not clarify the exact data required to secure a partnership for the CYTOPE platform, instead emphasizing ongoing research collaborations and broad potential applications. Additionally, while discussing the transferrin modification for PRX012, the mechanistic hypotheses were presented as speculative, and no definitive evidence was provided.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
ALS
ATTR CM
BMS
Bristol Myers
CLEOPATTRA trial
CYTOPE technology
II TargetTau
II trial
III PARAISO
III trial
MTBR
Myers Squibb
NT proBNP
PARAISO trial
Phase II
Phase III
Slide
TDP CYTOPE
TDP aggregate
TargetTau trial
cell
completion
dose
function
month
pathology
placebo
receptor technology
result Phase
royalty
sale
targeting
transferrin
trial patient
PRTA Transcript
Prothena Corporation plc (PRTA) Q4 2025 Earnings Call Transcript
Unknown2-19
The earnings call reflects a mixed sentiment. Financial performance shows prudent capital utilization but also a significant net loss. The Q&A highlights promising developments in product trials and partnerships, but also reveals management's reluctance to provide detailed guidance, creating uncertainty. The share redemption plan indicates potential shareholder value but lacks immediate impact. Overall, the stock is likely to remain neutral, with no strong catalysts for significant movement. The market cap suggests moderate sensitivity to these factors.
Prothena Corporation plc (NASDAQ:PRTA) Q4 2024 Earnings Call Transcript
Unknown2-21
Earnings call shows EPS and net loss near lower guidance, no share repurchase, and uncertainties in AL amyloidosis treatment. Q&A reveals lack of specifics on critical issues and unclear management responses, indicating potential risks. Although management is optimistic about birtamimab's market potential, the financial metrics and lack of guidance clarity suggest a negative sentiment. Given the small-cap nature of the company, this could lead to a stock price decline of -2% to -8%.
Prothena Corporation plc (PRTA) Q4 2023 Earnings Call Transcript
Positive2-16
The company's financial performance was better than expected, with efficient resource management and strong cash reserves. The Q&A session highlighted positive trial developments, such as strong patient enrollment and promising safety profiles, despite some management evasiveness on specific data updates. These factors, combined with the company's market cap, suggest a positive stock price movement within the 2% to 8% range.
Prothena Corporation plc (PRTA) Q4 2022 Earnings Call Transcript
Neutral2-24
PRTA Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
